Economic TimesLean R·
US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes
Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks last month regarding its experimental Duchenne muscular dystrophy treatment. New 24-month data will focus on improving upper limb muscle function for the drug. Analysts view the FDA's willingness to review this information as a positive development. Capricor is pacing commercial launch spending while awaiting regulatory clarity on the drug.
Read at Economic Times →
